StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report released on Friday. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance NYSE NAVB opened at $0.08 on Friday. Navidea Biopharmaceuticals has a 1 year low of $0.06 and a 1 year high of $0.39. The […]
There may be considerably rich pickings for investors if they investigate the sub-penny stock space a bit more closely. However, it is also important to do the right sort of research. Here is a quick look at five of
StockNews com Initiates Coverage on Navidea Biopharmaceuticals (NYSE:NAVB) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Price Performance NAVB opened at $0.08 on Wednesday. The company’s 50 day simple moving average is $0.09 and its two-hundred day simple moving […]
- Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in people living with ALSP expected in fourth quarter of 2023 - - Small molecule TREM2 agonist IND submission and.